Review
Copyright ©2011 Baishideng Publishing Group Co.
World J Cardiol. Mar 26, 2011; 3(3): 84-92
Published online Mar 26, 2011. doi: 10.4330/wjc.v3.i3.84
Figure 1
Figure 1 EUCATAX design and characteristics. PLGA: Poly(D,L-lactic-co-glycolic acid).
Figure 2
Figure 2 EUCATAX randomized trial design. Modified form Rodriguez et al[39]. Pts: Patients; PCI: Percutaneous coronary interventions; PES: Paclitaxel eluting stent; BMS: Bare-metal stent.
Figure 3
Figure 3 Results at 18 mo. EUCATAX trial. AMI: Acute myocardial infarction; MACCE: Major adverse cardiovascular events; TVF: Target vessel failure; TLR: Target lesion revascularisation; TVR: Target vessel revascularisation; PES: Paclitaxel-eluting stents; BMS: Bare-metal stent.